K Hertogs

Author PubWeight™ 51.11‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol 2001 3.05
2 High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients. J Clin Microbiol 2001 2.45
3 A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance. Antimicrob Agents Chemother 1999 2.08
4 Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting. AIDS 1999 1.85
5 High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Côte d'Ivoire. J Acquir Immune Defic Syndr 2001 1.71
6 Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naïve HIV-1 infected US military personnel. AIDS 2000 1.53
7 Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples. AIDS 2000 1.43
8 [Virological evaluation of treating HIV-infected patients with (combinations of) antiretroviral drugs at the Amsterdam Academic Medical Center, 1996/'97]. Ned Tijdschr Geneeskd 1998 1.39
9 Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: association with therapy failure. J Infect Dis 1998 1.26
10 Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters. Proc Natl Acad Sci U S A 2001 1.26
11 Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS 2000 1.23
12 Correlation between viral resistance to zidovudine and resistance at the reverse transcriptase level for a panel of human immunodeficiency virus type 1 mutants. J Virol 2001 1.20
13 Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples. Nucleosides Nucleotides Nucleic Acids 2001 1.19
14 Genotypic and phenotypic evidence of different drug-resistance mutation patterns between B and non-B subtype isolates of human immunodeficiency virus type 1 found in Brazilian patients failing HAART. Virus Genes 2001 1.16
15 Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-up. Antivir Ther 2001 1.14
16 Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the nonnucleoside reverse transcriptase inhibitor loviride. Antimicrob Agents Chemother 1998 1.12
17 The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors. AIDS 1998 1.11
18 Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen. AIDS 2000 1.10
19 Drug-resistant reverse transcriptase genotyping and phenotyping of B and non-B subtypes (F and A) of human immunodeficiency virus type I found in Brazilian patients failing HAART. Virology 2000 1.03
20 HIV drug susceptibility and treatment response to mega-HAART regimen in patients from the Frankfurt HIV cohort. Antivir Ther 2000 1.01
21 The impact of individual human immunodeficiency virus type 1 protease mutations on drug susceptibility is highly influenced by complex interactions with the background protease sequence. J Virol 2009 0.98
22 Lateral bead-chain urethrocystography after successful and unsuccessful colposuspension. Br J Obstet Gynaecol 1985 0.97
23 Primary genotypic and phenotypic HIV-1 drug resistance in recent seroconverters in Madrid. J Acquir Immune Defic Syndr 2001 0.96
24 Despite high concordance, distinct mutational and phenotypic drug resistance profiles in human immunodeficiency virus type 1 RNA are observed in gastrointestinal mucosal biopsy specimens and peripheral blood mononuclear cells compared with plasma. J Infect Dis 2000 0.92
25 Resistance profiles in patients with viral rebound on potent antiretroviral therapy. J Infect Dis 2000 0.92
26 Resistance to antiretroviral therapy among patients in Uganda. J Acquir Immune Defic Syndr 2001 0.91
27 Maternal perception of fetal motor activity. Br Med J 1979 0.90
28 Evaluation of lymph node virus burden in human immunodeficiency virus-infected patients receiving efavirenz-based protease inhibitor--sparing highly active antiretroviral therapy. J Infect Dis 2000 0.88
29 Transfection of a rat hepatoma cell line with a construct expressing human liver annexin V confers susceptibility to hepatitis B virus infection. Hepatology 1999 0.85
30 The use of desmopressin (DDAVP) for nocturia in women with multiple sclerosis. J Neurol Neurosurg Psychiatry 1983 0.85
31 Myocardial ischaemia after withdrawal of salbutamol for pre-term labour. Lancet 1979 0.84
32 Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure. AIDS Res Hum Retroviruses 2001 0.84
33 Distribution of K103N and/or Y181C HIV-1 mutations by exposure to zidovudine and non-nucleoside reverse transcriptase inhibitors. J Antimicrob Chemother 2001 0.82
34 Performance of drug resistance assays in testing HIV-1 non-B subtypes. Clin Microbiol Infect 2003 0.82
35 Sinusoidal rhythm caused by fetal hemorrhage during fetoscopy. J Perinat Med 1984 0.81
36 Impact of HIV type 1 drug resistance mutations and phenotypic resistance profile on virologic response to salvage therapy. AIDS Res Hum Retroviruses 2001 0.80
37 R211K and L214F do not invariably confer high level phenotypic resistance to thymidine analogs in zidovudine-naive patients with M184V. J Acquir Immune Defic Syndr 2001 0.80
38 Acute congestive cardiac failure in a hypertensive woman receiving salbutamol for premature labour. Br Med J 1980 0.80
39 Hepatitis delta virus attaches to human hepatocytes via human liver endonexin II, a specific HBsAg binding protein. J Viral Hepat 1994 0.78
40 Host and tissue tropism of hepatitis B virus. Liver 1992 0.78
41 Phenotypic cross-resistance to nelfinavir: the role of prior antiretroviral therapy and the number of mutations in the protease gene. AIDS Res Hum Retroviruses 2001 0.77
42 Failure of a ritonavir plus saquinavir-based rescue regimen precludes the use of protease inhibitors. AIDS 2000 0.76
43 Influence of the administration of human annexin V on in vitro binding of small hepatitis B surface antigen to human and to rat hepatocytes and on in vitro hepatitis B virus infection. J Viral Hepat 2000 0.76
44 Prevalence of HIV-1 drug resistance in antiretroviral-naive patients: a prospective study. AIDS 2001 0.76
45 Resistance analyses in HIV infected patients with a history of multiple antiretroviral treatment regimens. Sex Transm Infect 2001 0.75
46 Hepatitis B virus: specific binding and internalization of small HBsAg by human hepatocytes. J Gen Virol 1995 0.75
47 The safety of fetoscopy: (I). Effect of umbilical vessel puncture on the fetal heart rate and cord histology. Prenat Diagn 1983 0.75
48 RT-PCR for Amplification of Specific Fragments of HIV-1 Genome. Methods Mol Med 2000 0.75
49 Mechanism of urinary continence after colposuspension: barrier studies. Br J Obstet Gynaecol 1985 0.75
50 Low prevalence of antiretroviral drug resistance among HIV-1 seroconverters in London, 1984-1991. J Infect 2002 0.75
51 Supraventricular tachycardia in utero with two-to-one block in fetal monitor. Lancet 1981 0.75